Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
AVROBIO Inc
NASDAQ AVRO
Data sourced from
and
and
AVROBIO Inc Total Liabilities to Total Assets Ratio for the year ending December 31, 2023: 0.06
AVROBIO Inc Total Liabilities to Total Assets Ratio is 0.06 for the year ending December 31, 2023, a -77.14% change year over year. The total liabilities to total assets ratio measures the proportion of total liabilities to total assets. It is calculated by dividing the total liabilities by the total assets. This ratio provides insights into the company's financial leverage and the proportion of its assets financed by liabilities. A higher ratio indicates a higher level of financial risk and reliance on liabilities for asset acquisition.
-
AVROBIO Inc Total Liabilities to Total Assets Ratio for the year ending December 31, 2022 was 0.27, a 63.10% change year over year.
-
AVROBIO Inc Total Liabilities to Total Assets Ratio for the year ending December 31, 2021 was 0.17, a 170.71% change year over year.
-
AVROBIO Inc Total Liabilities to Total Assets Ratio for the year ending December 31, 2020 was 0.06, a -13.89% change year over year.
-
AVROBIO Inc Total Liabilities to Total Assets Ratio for the year ending December 31, 2019 was 0.07, a -14.54% change year over year.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: AVRO
| CEO | Mr. Geoff MacKay BSc |
| IPO Date | June 21, 2018 |
| Location | United States |
| Headquarters | Building 300, Cambridge, MA, United States, 02139 |
| Employees | 13 |
| Sector | Healthcare |
| Industry | Biotechnology |
Description
AVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Key trends
Similar companies
Hepion Pharmaceuticals Inc
NA
NA
StockViz Staff
September 20, 2024
Any question? Send us an email